RxDoctor Payments Data

Adrienne Phillips, MD

Hematology & Oncology · New York, NYNPI 1619056157

Payments from drug & device makers

$99,516in general payments, 2019–2025

Across 126 payments — averaging $789.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$29K
  • Gilead$14K
  • Genentech USA, Inc.$12K
  • Genmab U.S., Inc.$10K
  • Beigene USA, Inc.$9K
  • Incyte Corporation$7K
  • plus $19K from 11 others

What the payments were for

  • Consulting fees$54,31255%
  • Speaking & faculty fees$28,16128%
  • Travel & lodging$13,37613%
  • Food & beverage$3,5684%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$99,516 in reported general payments places this provider in the 75th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York

Medicare billing

Part B allowed, 2024
$20,318
Medicare patients
49
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrukinsaZanubrutinib53$750,602
RevlimidLenalidomide30$483,669
VenclextaVenetoclax22$374,325
ImbruvicaIbrutinib19$313,556
PomalystPomalidomide11$255,673
CalquenceAcalabrutinib Maleate11$149,507
Lenalidomide11$100,934
EliquisApixaban11$6,607
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim23$286
Acyclovir25$196
Allopurinol11$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$9,281$750,60253 claims
Bristol Myers SquibbRevlimid$29,168$483,66930 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$99$313,55619 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$6,456$255,67311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 967 hematology & oncology providers in New York.

Other hematology & oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →